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Abstract
Background: Levosimendan (L) is used in clinical practice for the treatment of severe heart
failure (HF); it has inotropic and vasodilatory effects, without increasing myocardial oxygen
consumption. In acute HF, levosimendan improves hemodynamic parameters; previous stu-
dies have demonstrated that it has favorable effects on left ventricular (LV) diastolic function.
The aim of our study was to evaluate the effect of on LV long-axis function that represents the
earlier marker of diastolic dysfunction.
Methods: We enrolled 41 patients (age 62 ± 12 years) admitted to our Department for acute
HF, NYHA class IV and severe LV dysfunction. Twenty-six patients were treated with L
(0.1 µg/kg/min ev for 24 h without loading dose) and 15 patients were treated with standard
therapy (C). We evaluated clinical, blood exams and echocardiographic parameters at baseline
and one week after L or C treatment.
Results: Baseline demographic, clinical and biochemical data were similar in both groups.
After one week, the L group had shown a significant improvement in NYHA class and a redu-
ction of pro-B-type natriuretic peptide (pro-BNP). In echocardiographic study, we observed an
improvement in LV longitudinal function (p < 0.05) and LV ejection fraction (p < 0.05) with
a reduction of E/E’ (p < 0.05) in the L group. We divided the L group into ischemic and non-
-ischemic patients and we demonstrated a significant increase in systolic function in the for-
mer. No differences were found between subgroups in diastolic function.
Conclusions: L therapy, without loading dose, improves NYHA class and ventricular func-
tion in patients with acute HF; we believe that these prolonged hemodynamic effects are due to
active metabolities of L. (Cardiol J 2011; 18, 5: 532–537)
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Introduction
Heart failure (HF) is a public health problem
with increasing incidence, poor prognosis and fre-
quent need for re-hospitalization [1, 2]. Intravenous
positive inotropic agents play an important role in
treating acute decompensation of chronic heart fail-
ure (CHF) [3–5]. Levosimendan (L) is a calcium
sensitizer with positive inotropic properties that
works on the sensibilization of Ca2+ channels of
myocites increasing intracellular Ca2+ concentration
[6, 7]. The intracellular Ca2+ binds troponin C, re-
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sulting in a stabilization of the link between actin
and myosin, improving the contractility during sys-
tole [8]. As an additional effect, L opens the K+-ATP
dependent channels on cytosolic and mitochond-
rial membranes, increases K+ concentration in the
mytocondrial cytosol, and thus may delay apopto-
sis of myocites in HF patients [9, 10].
Left ventricular (LV) long-axis function repre-
sents the expression of subendocardial twitch; it has
been demonstrated that it is an earlier marker, even
more than ejection fraction (EF), of LV dysfunction.
Little data exists on the effects of L on echocardio-
graphic parameters of LV systolic and diastolic func-
tion in patients with advanced HF. Parissis et al.
[11] demonstrated an improvement of LV diastolic
function evaluated with echocardiographic para-
meters such as mitral E/A and E/E’ ratio after L the-
rapy; in addition, the authors showed an increasing
LV deceleration time and isovolumic relaxation
time after L therapy [12].
Heart failure guidelines suggest the use of L
with a loading dose if systolic blood pressure (SBP)
is over 100 mm Hg [3]. The pharmacokinetics of L
are linear and the plasma concentration of the drug
increases in a dose-proportional manner following
single dose i.v. administration and infusion of the
drug [13, 14]. Data from non-invasive studies has
shown that the maximal hemodynamic response to
L is 24–48 h after stopping infusion [15, 16]. The
prolonged hemodynamic action of L is due to the
formation of active metabolities; for this reason,
patients with HF can have hypotensive episodes
even after stopping the drug. No data exists about
the administration of L intravenously without a load-
ing dose in patients with acute HF. The aim of our
study was to investigate the use of L without a load-
ing dose in a cohort of end-stage CHF patients ad-
mitted to our institution for acute decompensation
HF compared to standard therapy, and its effect on
clinical, blood exams and echocardiographic param-
eters of diastolic and systolic function.
Methods
Study population
We evaluated 41 patients (age 62 ± 12 years)
with acute NYHA class IV HF and severe LV dys-
function (LVEF < 30%). Informed consent was
obtained from all subjects.
Exclusion criteria were: severe LV outflow
obstruction; SBP < 80 mm Hg; heart rate > 130/
/min; recent myocardial infarction (< eight weeks)
or active myocardial ischemia; serum creatinine le-
vel higher than 2.5 mg/dL or dialysis; hepatic failure;
acute or chronic infectious or inflammatory diseas-
es. All patients had not received digoxin or other
parenteral positive inotropics but only HF standard
therapy, as shown in Table 1. Twenty-six patients
were treated with L therapy, administered as con-
tinuous 24-h infusion at 0.1 µg/kg/min, without an
intravenous loading dose, and 15 patients, the con-
trol group (C), were treated with standard therapy
only. The decision to administer L without a load-
ing dose was based on clinical assessment of the
patients.
In the L group, 16 and ten patients had post-
-ischemic and idiopathic cardiomyopathy respec-
tively; in the C group, ten and five patients had post-
-ischemic and idiopathic cardiomiopathy, respec-
tively.
Ultrasound measurements
Standard echocardiography performed in all
patients included the evaluation of mitral annular
motion by tissue Doppler imaging (TDI) and
M-mode, using SONOS 5500 equipment (Hewlett
Packard, Andover, MA, USA) with a phases array
transducer of 2.5 MHz and TDI technology.
Echocardiographic exams were performed by an
experienced echocardiographer physician blinded to
all data. Recordings were acquired with subjects in
the left lateral decubitus during shallow respiration
or end expiratory apnea.
Echocardiography was performed at baseline
and one week after L or standard treatment. LV
systolic function was estimated by LVEF using the
biplane modified Simpson’s method [17] and the
long-axis function by TDI S’ wave [18] and M-mode
mitral annular plane systolic excursion (MAPSE)
[19], averaging excursion amplitudes recorded at
the four mitral annular sites. Tricuspid annular
plane systolic excursion (TAPSE) was also mea-
sured using two-dimensionally guided M-mode
imaging from the apical four-chamber view.
LV diastolic function was estimated by pulsed
wave (PW) Doppler on transmitral flow assessing
peak velocities in early (E) and late diastole (A),
E/A ratio, deceleration time of E wave (DT) and TDI
E’ (early) and A’ (late) waves [19]. The E/E’ ratio was
also calculated and used as an index of LV filling
pressures [20, 21].
Blood exams
Blood exams, included B-type natriuretic pep-
tide (pro-BNP) levels, were performed at baseline
and one week after L or standard treatment.
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Statistical analysis
Statistical analysis was performed using STAT-
VIEW 5.0. Quantitative values were expressed as
mean ± standard deviation and qualitative values
as %. The c2 test or Fisher’s exact test was used for
categorical values between two groups, the Student’s
t test or Mann-Whitney U test was utilized to com-
pare the continuous variables between groups. The
paired t test or Wilcoxon’s paired test was used to
compare values before and after drug administration.
Correlation analysis was performed using the Pear-
son’s correlation coefficients. A p value of < 0.05 was
considered statistically significant.
Results
There were no differences in baseline demo-
graphic, clinical or blood exams between the two
groups (Table 1). During L infusion, we did not ob-
serve severe hypotensive episodes compared to
standard therapy. Baseline echocardiographic para-
meters did not differ, except for MAPSE which was
higher in the C group than the L group (9 ± 3 mm vs
6 ± 1 mm, p = 0.03) as shown in Table 2.
After one week, both the L group and the
C group showed a significant improvement in NYHA
functional class (L IV vs III, p = 0.01); in the L group
we obtained a significant reduction of pro-BNP levels
(8,174 ± 9,226 vs 4,335 ± 7,947, p = 0.02) compared
to the C group (5,713 ± 3,124 pg/mL vs 3,191 ±
± 1,936 pg/mL, p = NS).
Echocardiographic evaluation of the L group
demonstrated a significant increase in MAPSE (6 ±
± 1 mm vs 9 ± 2 mm, p = 0.01; Fig. 1), LVEF (24.6 ±
± 4.8% vs 27.6 ± 4.6%, p = 0.02) and an E/E’ ratio
reduction (14.66 ± 4.31 vs 8.34 ± 3.6, p = 0.02; Fig. 2).
TAPSE didn’t improve significantly (14 ± 6 mm vs
16 ± 0.4 mm, p = NS). In the C group, after one
week, LVEF (25.6 ± 4.4% vs 29 ± 6.4%, p = NS),
MAPSE (9 ± 3 mm vs 9 ± 2 mm, p = NS), TAPSE
(15 ± 6 mm vs 15 ± 6 mm, p = NS) and E/E’ ratio
(14.5 ± 0.6 vs 13.7 ± 0.8, p = NS) had improved,
but not significantly.
We divided the L group into ischemic and non-
-ischemic cardiomyopathy and we demonstrated
a significant increase in MAPSE (6 ± 1 mm vs 8 ±
± 3 mm, p = 0.02) in the ischemic vs the non-is-
chemic subgroup (8 ± 2 mm vs 9 ± 3 mm, p = NS).
No significant differences appeared between the is-
chemic/non-ischemic subgroups in diastolic myo-
cardial function or LV filling pressure.
Discussion
In our study, we evaluated the efficacy of L,
administered without loading dose, independently
Table 1. Baseline characteristics of levosimendan (L) and standard therapy (C) groups.
Levosimendan (n = 26) Standard therapy (n = 15)
Age (years) 64±7 68±9
Sex, male 15 (58%) 9 (60%)
Body mass index [kg/m2] 26±1.1 28±1.8
Ischemic/non-ischemic patients 16/10 10/5
New York Heart Association IV IV
Pro-BNP [pg/mL] 8,174±9,226 5,713±3,124
Systolic blood pressure [mm Hg] 98±6 102±4
Diastolic blood pressure [mm Hg] 64±6 70±12
Heart rate [bpm] 70±11 80±8
Medicaments:
Diuretics (furosemide)  26 (100%)  15 (100%)
Angiotensin converting enzyme inhibitors 23 (88%) 14 (93%)
Angiotensin receptor blockers 5 (19%) 3 (20%)
Beta-blocker 20 (77%) 9 (60%)
Spironolactone 12 (46%) 8 (53%)
Aspirin 21 (81%) 11 (73%)
Amiodarone 10 (38%) 6 (40%)
Anticoagulants 6 (23%) 4 (27%)
Statin 20 (77%) 12 (80%)
Data is expressed as mean ± standard deviation or percentage
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of values of baseline blood pressure, compared to stan-
dard therapy (C) in patients with acute decompensat-
ed HF. We analysed changes in clinical, biochemical
and echocardiographic parameters.
It is well demonstrated that L improves symp-
toms [22] and reduces mortality [23] during both
acute HF and CHF if administered with a loading
dose. Our study demonstrated that continuous i.v.
Table 2. Echocardiographic parameters before and after treatment in the levosimendan (L) and
control groups (C).
Levosimendan (n = 26) Standard therapy (n = 15)
Time 0 1 week Time 0 1 week
LVEDD [mm] 71±9 70±9† 69±11 69±8†
LVESD [mm] 60±10 59±11† 58±11 51±8†
LVEF [%] 24±5 27±4* 25±4 29±6†
E/A 1.6±0.5 1.1±0.8† 2.4±0.4 2.3±0.6†
E/E’ 14.6±4.3 8.3±3.6* 14.5±0.6 13.7±0.8†
IVRT 74±24 88±40† 51±42 56±12†
DT 133±54 154±44† 140±18 139±32†
MAPSE [mm] 6±1 8±2* 9±3 9±2†
TAPSE [mm] 14±5 16±4† 14±6 15±6†
SBP [mm Hg] 111±6 107±10† 105±10 110±10†
DBP [mm Hg] 64±6 60±6† 70±12 68±10†
Heart rate [bpm] 74±12 71±8† 80±8 73±9†
New York Heart Association IV III IV III
Pro-BNP [pg/mL] 8,174±9,226 4,335±7,947* 5,713±3,124 3,191±1,936†
Data is expressed as mean ± standard deviation; LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-systolic diameter;
LVEF — left ventricular ejection fraction; IVRT — isovolumetric relaxation time; DT — deceleration time; MAPSE — mitral annular plane systolic
excursion; TAPSE — tricuspid annular plane systolic excursion; SBP — systolic blood pressure; DBP — diastolic blood pressure; *p < 0.05; †p = NS
Figure 1. MAPSE variations in levosimendan (L) and
standard therapy (C) groups after one week of treat-
ment; *p < 0.05; †p = NS
Figure 2. E/E’ variations in levosimendan (L) and stan-
dard therapy (C) groups after one week of treatment;
*p = 0.02; †p = NS
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infusion of L leads to an improvement in clinical
NYHA class, pro-BNP blood levels and echocardio-
gaphic indices of ventricular function after seven days.
Unlike other studies performed with a loading dose
of L, we had these effects without an increase in hy-
potension episodes [24].
Several studies have suggested that BNP or
pro-BNP levels at the time of hospitalization have
a prognostic value in patients with HF [25–27]; on
the other hand, a decrease in BNP levels during
hospitalization is associated with a reduction in
deaths and rehospitalizations after 30 days [28]. The
increase of blood pro-BNP levels was due to myo-
cardial wall stress condition and directly related to
LV filling pressures [29, 30]. Our data demonstrat-
ed a significant decrease of pro-BNP levels seven
days after L therapy compared to C, underscoring
the favorable effects of L in acute HF. The decrease
of pro-BNP levels is associated with an increase in
echocardiographic parameters such as EF, MAPSE
and E/E’.
Few echocardiographic studies have analyzed
the effect of L on LV function, in particular its ef-
fects on LV longitudinal function. LV systolic con-
traction is a complex phenomenon resulting from
interaction among differently arranged myocardial
layers, leading to simultaneous longitudinal and cir-
cumferential shortening, radial thickening, and
twisting [31]. Because of the high vulnerability of
longitudinal subendocardial fibers to several injury
mechanisms, assessment of the longitudinal com-
ponent of LV shortening is an important parameter
for the early detection of LV contractile impairment
[32]. Using TDI and M-mode analysis, we can eva-
luate accurately LV longitudinal systolic and dia-
stolic performance. In our study, after L treatment
we obtained an improvement of LVEF and MAPSE
and a reduction of E/E’ ratio.
These results are related to the effect of L on
LV filling pressures: cardiac output increases while
pulmonary wedge pressure decreases, with a reduc-
tion of both pre-load and post-load forces [33].
After dividing the L group into ischemic and
non-ischemic cardiomyopathy, we found a higher
increase of MAPSE in the ischemic vs the non-is-
chemic subgroup, with no changes in diastolic func-
tion parameters or LV filling pressure.
An ischemic heart contains several types of
cells: healthy, stunned and hibernated. Hibernated
cells are missing calcium-related proteins, so the
calcium release is altered [34]. Levosimendan
works in healthy muscle cells improving the intrac-
ellular calcium concentration so it increases muscle
contraction without increasing oxygen consumption.
A previous study demonstrated that L can also re-
duce apoptosis by activating mitochondrial KATP chan-
nels [35] and this suggests a mechanism of cardiac
myocytes protection. This can explain our results in
ischemic compared to non-ischemic patients.
Limitations of the study
Our results indicate that L may have positive
effects in HF without a loading dose in terms of safety
and efficacy. The present study, however, has some
limitations due to the small number of patients, es-
pecially the subgroups. Our study shows however
that L can be safely administered in patients with
end-stage HF. Further studies enrolling more pa-
tients are needed to validate these results.
Conclusions
Heart failure guidelines suggest the use of L
with loading dose if SBP > 100 mm Hg; we demon-
strated that continuous i.v. L administration with-
out loading dose can improve NYHA class, EF and
diastolic function compared to standard therapy with
a decrease in the number of hypotension episodes. In
particular, we showed that LV longitudinal function
increases and LV filling pressure reduces significantly.
These longitudinal function improvements were
greater in patients with post-ischemic rather than
idiopathic cardiomyopathies. We believe that these
prolonged hemodynamic effects are due to active meta-
bolities of levosimendan.
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